Photocure ASA - Photocure presenting at Nordic Health Care Conference 2011

Published: 5 December 2011Investor conferences


Oslo, Norway, 5 December 2011:

Photocure ASA (OSE: PHO), a specialty pharmaceutical company focused on photodynamic technologies in dermatology and cancer, will be presenting at the Nordic Health Care Conference 2011 with DNB Markets in Oslo, Norway on 6 December 2011.
Kjetil Hestdal, President & CEO of Photocure ASA, and Kathleen Deardorff, COO of Photocure ASA, will be presenting for the Company. The presentation will highlight the new Commercial strategy for Hexvix/Cysview. And will be available on Photocure's website at

For further information contact:

President & CEO Kjetil Hestdal
Tel: + 47 913 19 535, Email:

Mary Clark, Amber Bielecka, Hollie Vile
Tel: +44 207920 2361, Email:

About Photocure ASA

Photocure ASA is a worldwide leader in photodynamic technology. Listed on the Oslo Stock Exchange (OSE: PHO), Photocure is focused on photodynamic technologies in dermatology and cancer. The company strives to solve unmet needs by developing new and innovative solutions based on its patented Photocure Technology(TM). Photocure markets and sells its own products in selected markets and has developed strong partnerships with leading pharmaceutical companies on a regional and global basis. Photocure's bladder cancer diagnostic product, Hexvix is approved in Europe and the US. In addition, the company markets Allumera®, a photodynamic cosmetic in the US. Setting new standards for diagnosis and treatment of several different conditions, Photocure Technology(TM) is continuously being tested for new products and applications in cancer and dermatology. Allumera®, Photocure® and Hexvix® are registered trademarks of Photocure ASA. For more information about Photocure, visit

This information is subject of the disclosure requirements acc. to §5-12 vphl (Norwegian Securities Trading Act)

News and events